These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21835138)

  • 1. Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis.
    Oria M; Romero-Giménez J; Arranz JA; Riudor E; Raguer N; Córdoba J
    J Hepatol; 2012 Jan; 56(1):109-14. PubMed ID: 21835138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motor-evoked potentials in awake rats are a valid method of assessing hepatic encephalopathy and of studying its pathogenesis.
    Oria M; Chatauret N; Chavarria L; Romero-Giménez J; Palenzuela L; Pardo-Yules B; Arranz JA; Bodega G; Raguer N; Córdoba J
    Hepatology; 2010 Dec; 52(6):2077-85. PubMed ID: 20890898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
    Jalan R; Wright G; Davies NA; Hodges SJ
    Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
    Ventura-Cots M; Arranz JA; Simón-Talero M; Torrens M; Blanco A; Riudor E; Fuentes I; Suñé P; Soriano G; Córdoba J
    J Clin Gastroenterol; 2013; 47(10):881-7. PubMed ID: 23751856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats.
    Davies NA; Wright G; Ytrebø LM; Stadlbauer V; Fuskevåg OM; Zwingmann C; Davies DC; Habtesion A; Hodges SJ; Jalan R
    Hepatology; 2009 Jul; 50(1):155-64. PubMed ID: 19437490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats.
    Jover-Cobos M; Noiret L; Lee K; Sharma V; Habtesion A; Romero-Gomez M; Davies N; Jalan R
    J Hepatol; 2014 Mar; 60(3):545-53. PubMed ID: 24512823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interorgan metabolism of ornithine phenylacetate (OP)--a novel strategy for treatment of hyperammonemia.
    Dadsetan S; Sørensen M; Bak LK; Vilstrup H; Ott P; Schousboe A; Jalan R; Keiding S; Waagepetersen HS
    Biochem Pharmacol; 2013 Jan; 85(1):115-23. PubMed ID: 23103564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure.
    Ytrebø LM; Kristiansen RG; Maehre H; Fuskevåg OM; Kalstad T; Revhaug A; Cobos MJ; Jalan R; Rose CF
    Hepatology; 2009 Jul; 50(1):165-74. PubMed ID: 19554542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes.
    Safadi R; Rahimi RS; Thabut D; Bajaj JS; Ram Bhamidimarri K; Pyrsopoulos N; Potthoff A; Bukofzer S; Wang L; Jamil K; Devarakonda KR
    Clin Transl Sci; 2022 Jun; 15(6):1449-1459. PubMed ID: 35238476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats.
    Wright G; Vairappan B; Stadlbauer V; Mookerjee RP; Davies NA; Jalan R
    Liver Int; 2012 Mar; 32(3):410-9. PubMed ID: 22151131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ornithine phenylacetate revisited.
    Jover-Cobos M; Noiret L; Sharifi Y; Jalan R
    Metab Brain Dis; 2013 Jun; 28(2):327-31. PubMed ID: 23456516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway.
    Kristiansen RG; Rose CF; Fuskevåg OM; Mæhre H; Revhaug A; Jalan R; Ytrebø LM
    Am J Physiol Gastrointest Liver Physiol; 2014 Nov; 307(10):G1024-31. PubMed ID: 25258408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.
    Kristiansen RG
    Metab Brain Dis; 2016 Dec; 31(6):1357-1358. PubMed ID: 27651377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats.
    Balasubramaniyan V; Wright G; Sharma V; Davies NA; Sharifi Y; Habtesion A; Mookerjee RP; Jalan R
    Am J Physiol Gastrointest Liver Physiol; 2012 Jan; 302(1):G145-52. PubMed ID: 21903766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.
    Kristiansen RG; Rose CF; Ytrebø LM
    Metab Brain Dis; 2016 Dec; 31(6):1269-1273. PubMed ID: 27339764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamine, myo-inositol, and organic brain osmolytes after portocaval anastomosis in the rat: implications for ammonia-induced brain edema.
    Cordoba J; Gottstein J; Blei AT
    Hepatology; 1996 Oct; 24(4):919-23. PubMed ID: 8855198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension.
    Jalan R; De Chiara F; Balasubramaniyan V; Andreola F; Khetan V; Malago M; Pinzani M; Mookerjee RP; Rombouts K
    J Hepatol; 2016 Apr; 64(4):823-33. PubMed ID: 26654994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ornithine aminotransferase inactivation by 5-fluoromethylornithine in rats following portacaval anastomosis.
    Therrien G; Sarhan S; Knödgen B; Butterworth RF; Seiler N
    Metab Brain Dis; 1994 Sep; 9(3):211-24. PubMed ID: 7838064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of behavioral changes in rats subjected to portacaval shunt with oral neomycin therapy.
    Conjeevaram HS; Nagle A; Katz A; Kaminsky-Russ K; McCullough AJ; Mullen KD
    Hepatology; 1994 May; 19(5):1245-50. PubMed ID: 8175148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of systemic oxidative stress leads to brain oedema in portacaval shunted rats.
    Bosoi CR; Tremblay M; Rose CF
    Liver Int; 2014 Oct; 34(9):1322-9. PubMed ID: 25354203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.